» Articles » PMID: 32128502

Successful Treatment with Rivaroxaban of an Extended Deep Vein Thrombosis Complicated by Pulmonary Embolism in a Patient with Familial Antithrombin III Deficiency: a Case Report

Overview
Date 2020 Mar 5
PMID 32128502
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with low levels of antithrombin III (AT III) are at an increased risk of developing arteriovenous thromboembolic disease.

Case Summary: We report a case of a 28-year-old woman who presented with a 1-week history of spontaneous right calf pain and swelling. A heterozygous AT III deficiency, phenotypically expressed as deep vein thrombosis, was reported in the patient's mother and sister. Blood workup revealed residual AT III activity at 58% with normal protein C and protein S levels. Computed tomographic angiography (CTA) revealed subsegmental bilateral pulmonary embolism (PE) and deep vein thrombosis in the right leg extending into the inferior vena cava up to the confluence of the left renal vein. Placement of an inferior vena cava filter was not considered. Given the patient's haemodynamic stability, anticoagulant therapy with 15 mg of rivaroxaban twice a day was initiated instead. Echocardiography after 10 days of treatment revealed complete resolution of the thrombus located in the inferior vena cava, while CTA revealed complete resolution of the PE.

Discussion: Patients with AT III deficiency are likely to be heparin-resistant and will require higher heparin doses or the administration of AT III replacement therapy for the treatment of thrombosis, both of which are associated with an increased risk for haemorrhagic complications. Direct factor Xa inhibition by rivaroxaban provided an alternative mechanism for anticoagulation, which was found to be particularly useful in this patient with familial AT III deficiency, deep vein thrombosis, and PE.

Citing Articles

Higher dose of rivaroxaban for the treatment of venous thromboembolism in a 15-year-old Asian child with antithrombin deficiency: A case report and literature review.

Liang C, Chen Y, Liu F, Yue Y, Du L Medicine (Baltimore). 2025; 104(9):e41629.

PMID: 40020143 PMC: 11875584. DOI: 10.1097/MD.0000000000041629.


A Feasibility Study on the Identification of Potential Biomarkers in Pulmonary Embolism Using Proteomic Analysis.

Granholm F, Bylund D, Shevchenko G, Lind S, Henriksson A Clin Appl Thromb Hemost. 2022; 28:10760296221074347.

PMID: 35043712 PMC: 8796107. DOI: 10.1177/10760296221074347.

References
1.
Spiess B . Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg. 2008; 85(6):2153-60. DOI: 10.1016/j.athoracsur.2008.02.037. View

2.
Konkle B, Bauer K, Weinstein R, Greist A, Holmes H, Bonfiglio J . Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003; 43(3):390-4. DOI: 10.1046/j.1537-2995.2003.00315.x. View

3.
Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N . 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43):3033-69, 3069a-3069k. DOI: 10.1093/eurheartj/ehu283. View

4.
Minami K, Kumagai K, Sugai Y, Nakamura K, Naito S, Oshima S . Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency. Intern Med. 2018; 57(14):2025-2028. PMC: 6096030. DOI: 10.2169/internalmedicine.0483-17. View

5.
Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View